BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9485043)

  • 1. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S; Kraft AS
    Cancer Res; 1998 Feb; 58(4):834-9. PubMed ID: 9485043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
    Engedal N; Korkmaz CG; Saatcioglu F
    Oncogene; 2002 Feb; 21(7):1017-27. PubMed ID: 11850819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
    Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
    Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
    DeMiguel F; Lee SO; Lou W; Xiao X; Pflug BR; Nelson JB; Gao AC
    Prostate; 2002 Jul; 52(2):123-9. PubMed ID: 12111703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
    You Z; Shi XB; DuRaine G; Haudenschild D; Tepper CG; Lo SH; Gandour-Edwards R; de Vere White RW; Reddi AH
    Cancer Res; 2006 Jan; 66(1):175-83. PubMed ID: 16397230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.